Pfizer bags a hormone-sensitive win
Talapro-3 could help move Talzenna into earlier prostate cancer.
J&J sidelines a novel project
The company’s TRPV1 antagonist looks doomed.
EAU 2026 – J&J strengthens its bladder hand
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
